Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Press Releases
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
Delayed Japan Exchange  -  01:00:00 2023-01-27 am EST
8149.00 JPY   -1.59%
08:00aDisappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre-Bell
MT
05:33aBiogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application for Alzheimer's Disease Drug
MT
01/26Eisai : Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
CommuniquÚs de presse de la sociÚtÚ EISAI CO., LTD.
01/26Eisai : Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer..
AQ
01/26European Medicines Agency accepts Marketing Authorization Application for lecanemab as ..
AQ
01/17Eisai : Aims to advance gastrointestinal cancer treatment with research across multiple tu..
PU
01/15Eisai, Biogen apply for Alzheimer's drug approval in Japan
AQ
01/12Eisai : Launches renewed sustainability page
PU
01/10BioArctic's partner Eisai submits marketing authorization application for lecanemab as ..
AQ
01/09Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approva..
AQ
01/09FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Tr..
AQ
01/07Explainer : New drug slows Alzheimer's but comes with caveats
AQ
01/06Eisai : Submits Supplemental Biologics License Application to FDA for Traditional Approval..
PU
01/06BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for..
AQ
01/06U.S. regulators OK Alzheimer's drug developed by Japan's Eisai
AQ
01/06US approves Alzheimer's drug that modestly slows disease
AQ
01/06Alzheimer's drug that modestly slows disease OK'd by FDA
AQ
01/06Eisai : FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathwa..
PU
2022BioArctic's partner Eisai publishes statement relating to article on lecanemab in Scien..
AQ
2022BioArctic's partner Eisai initiates BLA submission of data for lecanemab in China
AQ
2022Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United Stat..
AQ
2022Eisai : TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA« (perampanel) CIII IN UNITED STAT..
PU
2022Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensiv..
AQ
2022Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio ..
AQ
2022Eisai - eleven experts from leading medical institutions and eight experts from eisai p..
AQ
2022Eisai presents full results of lecanemab phase 3 confirmatory clarity ad study for earl..
AQ
2022Landmark Alzheimer's drug slows down disease in early stages
AQ
2022Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish F..
AQ
2022Drug slows Alzheimer's but can it make a real difference?
AQ
2022BioArctic's partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD..
AQ
2022Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's d..
AQ
2022Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Ar..
AQ
2022Eisai to present latest data on fycompa ciii at the 76th american epilepsy society annu..
AQ
2022Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) ..
AQ
2022To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadz..
AQ
2022Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clar..
AQ
2022Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid..
AQ
2022Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance..
AQ
2022Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Tre..
AQ
2022Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon
AQ
2022Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and ..
AQ
2022Altoida Celebrates Historic Day for Patients with Alzheimer's Disease
AQ
2022Alzinova AB interim report January - September 2022
AQ
2022Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA Monotherap..
AQ
2022Interim Report for the period July - September 2022
AQ
2022Eisai Completes Construction of Its New Injection/Research Building at Kawashima Indust..
AQ
2022Addf statement on topline results of phase 3 trial of amyloid-clearing drug lecanemab
AQ
2022Alzheimer's drug shows promise in early results of study
AQ
2022Eisai - lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing h..
AQ
2022Update1 : Alzheimer's drug proves effective in slowing symptoms, says Eisai
AQ
2022Alzheimer's drug proves effective in slowing symptoms, says Eisai
AQ
2022Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
AQ
2022Eisai : Lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing high..
PU
2022Lecanemab phase 3 Clarity AD study in early Alzheimer's disease meets primary and all k..
AQ
2022Eisai : Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheum..
AQ
2022Merck and eisai present results from phase 3 leap-002 trial evaluating keytruda plus le..
AQ
2022Eisai presents results of post-hoc analysis of eribulin mesylate at the european societ..
AQ
2022Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENV..
AQ
2022Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the Europ..
AQ
2022Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
AQ
2022Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and P..
AQ
2022C2n and eisai collaborate to build awareness and real-world evidence for blood-based as..
AQ
2022Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-b..
AQ
2022Eisai - baseball legend bernie williams teams up with eisai and advocacy partners to la..
AQ
2022Eisai : CONSOLIDATED FINANCIAL REPORT for the Three-Month Period Ended June 30,2022
PU
2022Eisai : FY 2022 (Ending March 31, 2023) First Quarter Financial Results Reference Data
PU
2022Merck and eisai provide update on phase 3 leap-002 trial evaluating keytruda (pembroliz..
AQ
2022Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and..
AQ
2022Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
AQ
2022Eisai : and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Ev..
PU
2022Latest data on lecanemab to be presented at Alzheimer's Association International Confe..
AQ
2022Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
AQ
2022Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
AQ
2022Eisai : To present the latest lecanemab data, including aria-e and subcutaneous formulatio..
PU
2022Interim Report for the period April - June 2022
AQ
2022Eisai Co., Ltd. - THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS..
AQ
2022U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application o..
AQ
2022The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alz..
AQ
1  2  3  4  5  6  7  8  9Next
Upcoming event on EISAI CO., LTD.